Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones
January 09, 2023 08:00 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small...
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219
January 04, 2023 09:00 ET
|
Biomea Fusion, Inc.
COVALENT-111, now underway in the US, has completed Phase I and is currently enrolling type 2 diabetes patients in the Phase II randomized, placebo-controlled portion of the trialBMF-219, an orally...
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes
December 14, 2022 16:30 ET
|
Biomea Fusion, Inc.
COVALENT-111, a Phase I/II clinical trial in patients with type 2 diabetes, already underway in Canada, will now activate sites in the USAs previously reported, the Phase I portion of COVALENT-111 has...
Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date
December 12, 2022 08:00 ET
|
Biomea Fusion, Inc.
BMF-500, an investigational third generation covalent FLT3 inhibitor, demonstrated preclinically: Picomolar affinity to activating FLT3 mutations including FLT3-ITD and various tyrosine kinase domain...
Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference
November 11, 2022 08:30 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”)(Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel...
Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights
November 07, 2022 16:27 ET
|
Biomea Fusion, Inc.
Continued to establish Biomea Fusion as the next-generation leader in covalent medicinesExpanded clinical development footprint of BMF-219, the company’s lead investigational, orally administered,...
Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting
November 03, 2022 09:19 ET
|
Biomea Fusion, Inc.
BMF-500, an investigational third generation covalent FLT3 inhibitor, has demonstrated preclinically that it may be the most potent and selective inhibitor of FLT3 evaluated to date: Greater...
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219
October 31, 2022 08:00 ET
|
Biomea Fusion, Inc.
BMF-219 is the first menin inhibitor to reach the clinic for type 2 diabetes. The Phase II portion of COVALENT-111 is designed to examine the capacity of BMF-219 to provide long-term glycemic control...
Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial
October 27, 2022 08:00 ET
|
Biomea Fusion, Inc.
COVALENT-101 now includes patients with relapsed/refractory (R/R) CLLBMF-219 is the first menin inhibitor in the clinic for CLLPreclinical data presented at ASCO 2022 demonstrated the potency of...
BMF-219 Enters the Clinic for KRAS Solid Tumors
October 14, 2022 09:00 ET
|
Biomea Fusion, Inc.
Biomea Fusion announces FDA clearance of Investigational New Drug (IND) application for covalent menin inhibitor BMF-219 in KRAS solid tumors.Biomea Fusion will now initiate a Phase I/Ib clinical...